Warren Stone was appointed President and Chief Operating Officer of NeoGenomics in April 2025. He joined Neo in November 2022 as President, Clinical Services and later became Chief Commercial Officer.
Warren is a highly accomplished enterprise leader with extensive global experience in the life science and diagnostic sectors, who most recently served as President of Americas at Ortho Clinical Diagnostics (now QuidelOrtho).
As a hands-on leader, Warren championed the development of an organizational growth culture and digital transformation of systems and tools, including a hybrid/digital go-to-market deployment model, delivering productivity, margin expansion, and accelerated revenue growth. With an emphasis on customer experience, Warren’s team won an independent industry ServiceTrak™ award for the Best Pre/Post-Sales and Customer Success in 2021 and 2022.
Before joining Ortho Clinical, Warren served as Senior Vice President of Research Americas for MilliporeSigma, where he developed a commercial growth strategy, advancing the business 40% above the market. He also drove a cross-functional digital transformation to address customer needs, resulting in more than $200 million in incremental revenue in 2.5 years.
What is Warren Stone's net worth?
The estimated net worth of Warren Stone is at least $1.32 million as of May 12th, 2025. Mr. Stone owns 108,280 shares of NeoGenomics stock worth more than $1,317,768 as of December 4th. This net worth evaluation does not reflect any other assets that Mr. Stone may own. Additionally, Mr. Stone receives an annual salary of $1,420,000.00 as President and Chief Operating Officer at NeoGenomics. Learn More about Warren Stone's net worth.
How old is Warren Stone?
Mr. Stone is currently 51 years old. There are 6 older executives and no younger executives at NeoGenomics. The oldest executive at NeoGenomics is Mr. Christopher Michael Smith BSc, CEO & Director, who is 61 years old. Learn More on Warren Stone's age.
What is Warren Stone's salary?
As the President and Chief Operating Officer of NeoGenomics, Inc., Mr. Stone earns $1,420,000.00 per year. The highest earning executive at NeoGenomics is Mr. Christopher Michael Smith BSc, CEO & Director, who commands a salary of $2,860,000.00 per year. Learn More on Warren Stone's salary.
How do I contact Warren Stone?
Has Warren Stone been buying or selling shares of NeoGenomics?
Warren Stone has not been actively trading shares of NeoGenomics within the last three months. Most recently, on Monday, May 12th, Warren Stone bought 5,700 shares of NeoGenomics stock. The stock was acquired at an average cost of $8.58 per share, with a total value of $48,906.00. Following the completion of the transaction, the chief operating officer now directly owns 108,280 shares of the company's stock, valued at $929,042.40. Learn More on Warren Stone's trading history.
Who are NeoGenomics' active insiders?
NeoGenomics' insider roster includes (), Douglas Brown (Insider), George Cardoza (Insider), Bruce Crowther (Director), Stephen Kanovsky (Director), Michael Kelly (Director), Mark Mallon (CEO), Kathryn McKenzie (CFO), Alicia Olivo (Executive Vice President, General Counsel & Business Development), David Perez (Director), Jeffrey Sherman (CFO), Robert Shovlin (Insider), Warren Stone (President and Chief Operating Officer), Lynn Tetrault (Director), and Anthony Zook (CEO). Learn More on NeoGenomics' active insiders.
Are insiders buying or selling shares of NeoGenomics?
During the last year, NeoGenomics insiders bought shares 7 times. They purchased a total of 70,600 shares worth more than $550,438.00. During the last year, insiders at the medical research company sold shares 1 times. They sold a total of 20,916 shares worth more than $250,992.00. The most recent insider tranaction occured on November, 25th when EVP Alicia C Olivo sold 20,916 shares worth more than $250,992.00. Insiders at NeoGenomics own 2.4% of the company.
Learn More about insider trades at NeoGenomics. Information on this page was last updated on 11/25/2025.
